

AD-A110 076

NAVAL AIR DEVELOPMENT CENTER WARMINSTER PA AIRCRAFT --ETC F/G 6/1  
STUDIES ON THE MECHANISM OF ACTION OF THE 'IN VITRO' PBB SUB X --ETC(U)  
OCT 81 M W SHUKLER, M G ZAWRYT

UNCLASSIFIED

NADC-81244-60

NL

1-1  
2-4



END  
DATE  
2 82  
DTIC



REPORT NO. NADC-81244-60



(12)

70



AD A110076

STUDIES ON THE MECHANISM OF ACTION OF THE IN VITRO PGB<sub>x</sub> EFFECT  
IV. THE EFFECT OF ORDER OF ADDITION OF PGB<sub>x</sub> TO ASSAY SYSTEM

Herman W. Shmukler, Ph.D.  
Naval Air Development Center  
Aircraft and Crew Systems Technology Directorate  
Biochemistry Research Team  
Warminster, Pennsylvania 18974

Margaret G. Zawryt, B.S.  
Hahnemann Medical College  
Philadelphia, Pennsylvania 19102

16 October 1981

Phase Report  
Airtask No. F58527803  
Work Unit No. EH810

SDTIC  
ELECTE  
JAN 26 1982  
A

APPROVED FOR PUBLIC RELEASE; DISTRIBUTION UNLIMITED

Prepared for  
Office of Naval Research  
Department of the Navy  
Arlington, Virginia 22217

DTIC FILE COPY

393532  
01 26 82 022


## NOTICES

**REPORT NUMBERING SYSTEM** – The numbering of technical project reports issued by the Naval Air Development Center is arranged for specific identification purposes. Each number consists of the Center acronym, the calendar year in which the number was assigned, the sequence number of the report within the specific calendar year, and the official 2-digit correspondence code of the Command Office or the Functional Directorate responsible for the report. For example: Report No. NADC-78015-20 indicates the fifteenth Center report for the year 1978, and prepared by the Systems Directorate. The numerical codes are as follows:

CODE	OFFICE OR DIRECTORATE
00	Commander, Naval Air Development Center
01	Technical Director, Naval Air Development Center
02	Comptroller
10	Directorate Command Projects
20	Systems Directorate
30	Sensors & Avionics Technology Directorate
40	Communication & Navigation Technology Directorate
50	Software Computer Directorate
60	Aircraft & Crew Systems Technology Directorate
70	Planning Assessment Resources
80	Engineering Support Group

**PRODUCT ENDORSEMENT** – The discussion or instructions concerning commercial products herein do not constitute an endorsement by the Government nor do they convey or imply the license or right to use such products.

APPROVED BY:

  
J. F. FUNARO  
CDR USN

DATE:

1/5/82

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER NADC-81244-60	2. GOVT ACCESSION NO. AD-A110076	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) Studies on the Mechanism of Action of the <i>in vitro</i> PGB <sub>x</sub> Effect IV. The Effect of Order of Addition of PGB <sub>x</sub> to Assay System	5. TYPE OF REPORT & PERIOD COVERED Phase Report	
	6. PERFORMING ORG. REPORT NUMBER	
7. AUTHOR(s) Herman W. Shmukler and Margaret G. Zawryt	8. CONTRACT OR GRANT NUMBER(s) N00014-81-WR10070	
9. PERFORMING ORGANIZATION NAME AND ADDRESS Naval Air Development Center Aircraft & Crew Systems Technology Directorate Warminster, PA 18974	10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS Airtask: RF58527803 Work Unit No.: EH810	
11. CONTROLLING OFFICE NAME AND ADDRESS Office of Naval Research Department of the Navy Arlington, VA 22217	12. REPORT DATE 16 October 1981	
	13. NUMBER OF PAGES 7	
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)	15. SECURITY CLASS. (of this report) UNCLASSIFIED	
	15a. DECLASSIFICATION/DOWNGRADING SCHEDULE	
16. DISTRIBUTION STATEMENT (of this Report)  APPROVED FOR PUBLIC RELEASE; DISTRIBUTION UNLIMITED		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) Prostaglandin Oxidative Phosphorylation Rat Liver Mitochondria (RLM) PGB <sub>x</sub> sub X deg		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) The mechanism of action of (PGB <sub>x</sub> ) in RLM oxidative phosphorylation was studied by varying the sequence of addition of (PGB <sub>x</sub> ). When (PGB <sub>x</sub> ) was added to RLM pre-exposed to hypotonic media at 27°C no restoration of phosphorylation was observed. When RLM were exposed to hypotonic conditions for 30 seconds before the addition of (PGB <sub>x</sub> ) and subsequently exposed to hypotonic conditions, the resulting phosphorylation was 60% of that observed in the normal system. From these results it is concluded that (PGB <sub>x</sub> ) functions in the <i>in vitro</i> (PGB <sub>x</sub> ) RLM assay system as a "protective" agent rather than a "restorative" agent.		


DD FORM 1 JAN 73 1473

EDITION OF 1 NOV 68 IS OBSOLETE  
S/N 0102-LF-014-6601

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)



S/N 0102- LF-014-6601

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

NADC-81244-60

TABLE OF CONTENTS

	<u>Page</u>
INTRODUCTION .....	2
EXPERIMENTAL .....	2
DISCUSSION .....	3
TABLE I .....	4
FIGURE 1 .....	5
REFERENCES .....	6



A

## INTRODUCTION

The possible use of PGB<sub>x</sub> (1, 2, 3) as a therapeutic agent in the treatment of human ischemic diseases was suggested by the favorable results from only a few animal experiments (4, 5, 6, 7, 8, 9, 10). Obviously before any human trials may be undertaken much more animal testing must be completed, and in addition, certain basic information concerning the mechanism of action of this drug must be known. At this stage of our knowledge of PGB<sub>x</sub> biochemistry, the possibility of successful elucidation of the in vivo mechanism of action appears remote. However, since the elucidation of the in vitro mechanism of PGB<sub>x</sub> might reveal an insight as to the in vivo mechanism, studies have been underway in this laboratory to define the in vitro PGB<sub>x</sub> effect.

Recently we reported that PGB<sub>x</sub> interacts with BSA (11) to form a complex that was inactive in the in vitro PGB<sub>x</sub> assay system (2, 3). Some of the experimental evidence published in that report was based on altering the sequence of the addition of PGB<sub>x</sub> and BSA in the assay system so that the PGB<sub>x</sub> and BSA could react before the addition of RLM. The results of these experiments then suggested the importance of the sequence of addition of the reactants of the test system, and that by studying this in detail some information concerning the mechanism of the in vitro PGB<sub>x</sub> effect might be realized.

## EXPERIMENTAL

Materials and Methods: PGB<sub>x</sub> Type II was synthesized and assayed for the in vitro PGB<sub>x</sub> effect as reported by Polis et al (2, 3). RLM was isolated and stored at 0° as described previously (2, 3). In this study the RLM were aged three days before use. All analytical methods used in this study were described previously (2, 3).

---

Note: Abbreviations used in this report are: RLM, rat liver mitochondria; BSA, bovine serum albumin; Pi, inorganic phosphate

**Results:** The effect of varying the order of addition of PGB<sub>x</sub> to the in vitro PGB<sub>x</sub> assay system was studied by measuring the changes in phosphorylating ability of RLM under various experimental conditions. Table I lists the composition and experimental conditions for the in vitro PGB<sub>x</sub> assay system (2). In the normal PGB<sub>x</sub> assay system, RLM were added to the hypotonic medium (Mixture A, Table I) containing the requisite amount of PGB<sub>x</sub>, and the mixture then incubated for the required time period. Phosphate acceptor (Mixture B, Table I) was then added and the mixture again incubated for 20 minutes. At the end of this time period the solution was deproteinized and the Pi esterified was measured. The extent of phosphorylation by this system was compared to that resulting from the following changes in experimental protocol: (a) RLM were incubated in Mixture A in the absence of PGB<sub>x</sub> for the required time period; at the end of this incubation period PGB<sub>x</sub> was added followed by the addition of Mixture B; the assay was then continued as above. (b) RLM was added to Mixture A and incubated for 30 seconds; PGB<sub>x</sub> was then added and the hypotonic incubation continued for the required time period; at the end of the incubation period Mixture B was added and the assay continued as above. Figure I shows the results of these tests. The curves shown are described in the legend of the figure. The normal assay curve of PGB<sub>x</sub> concentration shows the usual biphasic response with the maximum phosphorylation in the range of 2-10 µg/ml of reaction. When RLM were incubated in Mixture A in the absence of PGB<sub>x</sub>, the subsequent addition of PGB<sub>x</sub> did not restore the phosphorylation ability of the degraded RLM. When PGB<sub>x</sub> was added to the RLM incubated in Mixture A for 30 seconds, a biphasic phosphorylation curve was observed, however the maximum phosphorylation ability was only about 2/3 of the normal assay and in addition was shifted so that 10-20 µg PGB<sub>x</sub>/ml reaction were required.

#### DISCUSSION

In earlier reports on the physiological mechanism of PGB<sub>x</sub> action in both in vitro and in vivo systems it was suggested that PGB<sub>x</sub> functioned to reactivate damaged mitochondria (1, 2, 3, 8, 12) and thus reverse the pathological effects of ischemia. This interpretation appears contrary to the results reported in this study with isolated RLM subjected to hypotonic degradation. The results reported here show that RLM exposed to hypotonic media at 27° show a reduced capacity for oxidative phosphorylation. However when RLM are exposed to hypotonic media at 27° containing the required amount of PGB<sub>x</sub>, they maintain their capacity for oxidative phosphorylation. This phenomenon is the in vitro PGB<sub>x</sub> effect on RLM. In contrast when RLM are exposed to hypotonic media at 27°, the subsequent addition of PGB<sub>x</sub> has no effect on the recovery of phosphorylation activity of these RLM.

From the above results it may be concluded that PGB<sub>x</sub> functions in the in vitro assay system as a "protective" agent for RLM capacity for phosphorylation, rather than a "restorative" agent that reverses the degradative effects of exposure of RLM to hypotonic conditions.

NADC-81244-60

TABLE I

The Composition of the Medium for the Demonstration of the PGB<sub>x</sub>  
Effect on Mitochondrial Oxidative Phosphorylation


<u>Order of Addition</u>	<u>Mitochondrial Degrading Medium</u>	<u>Reaction Mixture</u>
Water	1.55 ml	1.55 ml
Phosphate Buffer pH 7.35	4.98 mM	4.55 mM
$\alpha$ -Ketoglutarate pH 7.35	14.93 mM	13.64 mM
MgSO <sub>4</sub>	4.98 mM	4.55 mM
Aged Mitochondria	1.99 mg/ml	1.82 mg/ml
Sucrose*	5.97 mM	5.45 mM
EDTA*	0.010 mM	0.009 mM
AMP	----	2.27 mM
ADP	----	2.27 mM
KCl	----	45.45 mM
Bovine Serum Albumin	----	0.68 mg/ml

Total Volume: 2.20 ml  
Temperature: 28°

Degradation Time: 5-20 minutes  
Reaction Time: 20 minutes

\*Added with mitochondria

FIGURE 1: The Effect of  $PC_{12}$  on the Phosphorylation Ability of BLM Exposed to Various Degradation Conditions. BLM aged three days in 0.3M sucrose at  $0^{\circ}$  were added to hypotonic media (Mixture A, Table 1) for 10 minutes at  $27^{\circ}$ . The phosphate acceptor mixture (Mixture B, Table 1) was then added and the incubation continued for twenty minutes. The Pi esterified was then determined by methods described previously (2, 3). The curves are identified as: +---+, normal  $PC_{12}$  assay curve; ○---○, BLM incubated in Mixture A with  $PC_{12}$  and  $PC_{12}$  added after ten minutes, just prior to the addition of Mixture B; ○---○, BLM incubated in Mixture A without  $PC_{12}$  for thirty seconds and  $PC_{12}$  then added and the incubation continued for nine minutes and thirty seconds before the addition of Mixture B.



REFERENCES

1. Polis, B. D., A. M. Grandizio and E. Polis: Some in vitro and in vivo Effects of a New Prostaglandin Derivative. Neurohumoral and Metabolic Aspects of Injury. Adv. in Exper. Med. and Biol., Plenum Press, New York 33:213-220 (1973).
2. Polis, B. D., S. F. Kwong, E. Polis and G. Nelson: Studies on PGB<sub>x</sub>: A Polymeric Derivative of Prostaglandin B<sub>1</sub>: I - Synthesis and Purification of PGB<sub>x</sub>. Report No. NADC-78235-60 (1978).
3. Polis, B. D., E. Polis and S. F. Kwong: Protection and Reactivation of Oxidative-Phosphorylation in Mitochondria by a Stable Free-Radical Prostaglandin Polymer (PGB<sub>x</sub>). Proc. Natl. Acad. Sci., 76:1598-1602 (1979).
4. Angelakos, W. T., B. D. Polis and R. L. Riley: Recovery After Coronary Ligation and Fibrillation in Primates Treated with a Prostaglandin Derivative. 47th Scientific Sessions American Heart Association, Abstracts, Dallas, Texas (1974).
5. Angelakos, E. T., B. D. Polis and R. L. Riley: Protection by a Prostaglandin Derivative from Mortality after Coronary Ligation from Ventricular Fibrillation in Primates. 6th International Congress of Pharmacology Abstracts, Helsinki, Finland (1975).
6. Angelakos, E. T., R. L. Riley and B. D. Polis: Recovery of Monkeys from Cardiogenic Shock After Myocardial Infarction with Ventricular Fibrillation. Effects of PGB<sub>x</sub>. Report No. NADC-77308-60 (1977).
7. Kolata, R. J.: The Effect of PGB<sub>x</sub> on Neurological Recovery from Cerebral Ischemia in Rabbits. Masters Thesis, Univ. of Penna. Veterinary School (1977).
8. Kolata, R. J. and B. D. Polis: Facilitation of Recovery from Ischemic Brain Damage in Rabbits by Polymeric Prostaglandin PGB<sub>x</sub>, a Mitochondrial Protective Agent. Physiol. Chem. and Physics 12, 551 (1980).
9. Yamazaki, H., M. M. Bodenheimer, V. S. Banka, J. Lewandowski and R. H. Helfant: The Effect of a New Prostaglandin (PGB<sub>x</sub>) on Length-tension Relationship Following Partial Coronary Occlusion and Reperfusion. Amer. Heart Assn., Abstracts 51st Scientific Session, Dallas, Texas, (1978).

NADC-81244-60

10. Moss, G., T. Magliochetti and R. Quarmby: Immediate Restoration of Central Nervous System Autonomic Cardio-pulmonary Control: Survival of "Lethal" Cerebral Hypoxia by Treatment with PGB<sub>x</sub>. Surgical Forum, 21:513 (1978).
11. Shmukler, H. W., M. G. Zawryt, W. Feely and E. Polis: The Interaction of PGB<sub>x</sub> with Bovine Serum Albumin. Physiol. Chem. and Physics, 13, 241 (1981).
12. Polis, B. D. and E. Polis: Novel Prostaglandin Derivatives, certain in vivo and in vitro Effects thereof and Processes for the Preparation of Same. United States Patent (19) (11) 4, 153, 808, 8 May 1979.

END

DATE  
FILMED

2-82

DTIC